Lanthanum carbonate: a new phosphate binder
GJ Behets, SC Verberckmoes… - Current opinion in …, 2004 - journals.lww.com
Lanthanum carbonate: a new phosphate binder : Current Opinion in Nephrology and
Hypertension Lanthanum carbonate: a new phosphate binder : Current Opinion in Nephrology …
Hypertension Lanthanum carbonate: a new phosphate binder : Current Opinion in Nephrology …
Vascular calcifications in uremia: old concepts and new insights
U Derici, AM El Nahas - Seminars in dialysis, 2006 - Wiley Online Library
The annual mortality rate in uremic patientscorrected for agesexand raceis significantly
higher than in the general population. This is primarily due to cardiovascular events …
higher than in the general population. This is primarily due to cardiovascular events …
Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment
AJ Hutchison, ME Barnett, R Krause, JTC Kwan… - Nephron Clinical …, 2008 - karger.com
Abstract Background/Aims: Lanthanum carbonate (LC, FOSRENOL®) is an effective
phosphate binder for which tolerability and a safety profile have been reported in …
phosphate binder for which tolerability and a safety profile have been reported in …
A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate
SM Sprague - Current medical research and opinion, 2007 - Taylor & Francis
Background: Obstacles to successful management of hyperphosphatemia in chronic kidney
disease include inadequate control of dietary phosphate and non-compliance with …
disease include inadequate control of dietary phosphate and non-compliance with …
[HTML][HTML] Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical …
H Shahbazian, H Shahbazian… - Nefrología (English …, 2011 - revistanefrologia.com
" autoresLista"=>" SILVIA CALD&# 201; S RUIS&# 193; NCHEZ, S. Cald&# 233; s Ruis&#
225; nchez, ROBERTO MARC&# 201; N LETOSA, R. Marc&# 233; n Letosa, YESIKA …
225; nchez, ROBERTO MARC&# 201; N LETOSA, R. Marc&# 233; n Letosa, YESIKA …
Lanthanum carbonate (Fosrenol®): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients
F Albaaj, AJ Hutchison - International journal of clinical practice, 2005 - Wiley Online Library
Approximately 70% of patients with end‐stage renal disease and dialysis have
hyperphosphataemia, which is associated with renal osteodystrophy, metastatic calcification …
hyperphosphataemia, which is associated with renal osteodystrophy, metastatic calcification …
Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients
F Albaaj, AJ Hutchison - Expert opinion on pharmacotherapy, 2005 - Taylor & Francis
Hyperphosphataemia is a usual accompaniment of end stage renal disease and dialysis, in
the absence of dietary phosphate restriction or supplemental phosphate binders. It is …
the absence of dietary phosphate restriction or supplemental phosphate binders. It is …
Renal osteodystrophy: review of the disease and its treatment
AMW El-Kishawi, AM El-Nahas - Saudi journal of kidney diseases …, 2006 - journals.lww.com
Renal osteodystrophy (ROD), which is most evident in patients on renal replacement
therapy (RRT), usually begins when the kidney function starts to deteriorate. The spectrum of …
therapy (RRT), usually begins when the kidney function starts to deteriorate. The spectrum of …
Comparison of dietary phosphate absorption after single doses of lanthanum carbonate and sevelamer carbonate in healthy volunteers: a balance study
P Martin, P Wang, A Robinson, L Poole… - American journal of …, 2011 - Elsevier
BACKGROUND: Lanthanum carbonate and sevelamer carbonate are noncalcium
phosphate binders used to treat hyperphosphatemia in patients with chronic kidney disease …
phosphate binders used to treat hyperphosphatemia in patients with chronic kidney disease …
Systemic lanthanum is excreted in the bile of rats
SJP Damment, M Pennick - Toxicology letters, 2007 - Elsevier
Lanthanum carbonate is a non-calcium-based oral phosphate binder for the control of
hyperphosphataemia in patients with chronic kidney disease Stage 5. As part of its pre …
hyperphosphataemia in patients with chronic kidney disease Stage 5. As part of its pre …